Tevogen Bio Finalizes 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance, Creates Significant Dilution Headroom

summarizeSummary

Tevogen Bio Holdings Inc. finalized a 1-for-50 reverse stock split, effective March 6, 2026, to meet Nasdaq's minimum bid price, but the move creates substantial potential for future share dilution.

check_boxKey Events

• Reverse Stock Split Finalized

  The company filed a Certificate of Amendment to effect a 1-for-50 reverse stock split, converting every 50 shares into one.

• Nasdaq Compliance Objective

  The reverse split is primarily intended to regain compliance with the Nasdaq Global Market's $1.00 minimum bid price requirement.

• Effective Date

  The reverse stock split will become effective at the open of business on March 6, 2026, with trading on a split-adjusted basis.

• Significant Dilution Headroom Created

  Post-split, outstanding shares will be approximately 4.05 million, while authorized shares remain at 800 million. If all authorized shares were issued, dilution would be approximately 19,661%.

auto_awesomeAnalysis

Tevogen Bio Holdings Inc. has officially implemented a 1-for-50 reverse stock split, a critical move to regain compliance with Nasdaq's minimum bid price requirement. While this action addresses the immediate threat of delisting, it often signals underlying financial distress. The company's stock is currently trading below its 52-week low, underscoring the challenging market sentiment. A significant concern for investors is the vast disparity between the post-split outstanding shares (~4 million) and the unchanged authorized shares (800 million), which creates immense headroom for future dilutive capital raises. If all authorized shares were issued, dilution would be approximately 19,661%. This substantial potential for dilution could exert significant downward pressure on the stock price over time, despite the immediate boost to the per-share price.